Anti-Amyloid Drug May Reduce the Risk of Early-Onset Alzheimer’s by 50%

Written by Tim Newman on March 20, 2025

Researchers are making waves in the fight against Alzheimer’s disease with a recent study on gantenerumab, an anti-amyloid drug. This could be revolutionary for those genetically predisposed to early-onset Alzheimer’s disease.

Key Points

• The study showed a potential 50% reduction in the risk of developing the disease for some participants.
• Gantenerumab works by targeting amyloid plaques in the brain, which are believed to contribute to cognitive decline.
• Long-term studies are necessary to confirm these findings across larger and more diverse populations.

Summary

In a groundbreaking trial involving individuals with dominantly inherited Alzheimer’s disease (DIAD), gantenerumab was tested to see if it could prevent or at least delay the onset of symptoms. This unique group of participants faces near-certain development of dementia in their early to mid-adulthood due to genetic factors. Encouragingly, after several years, the results revealed a significant reduction in amyloid beta levels in those treated with gantenerumab.

Although the initial study findings were promising with regard to amyloid plaque reduction, they did not translate into improvements in cognitive function as compared to the placebo group. Yet, extended treatment led to a marked reduction in Alzheimer’s risk for the most long-term users, providing hope for future therapies.

Opinion & Analysis

Despite the hopeful news regarding gantenerumab, experts urge caution. Chris Vercammen, MD, emphasizes the necessity for further extensive research to confirm these results across a wider demographic. The study of Alzheimer’s is complex, particularly concerning the role of amyloid-beta in the disease’s progression.

Moreover, while amyloid plaque reduction seems beneficial, possible side effects linked to anti-amyloid therapies, known as ARIA (amyloid-related imaging abnormalities), painted a mixed picture. Symptoms can range from headaches to nausea, pointing to the importance of ongoing monitoring during treatment.

In summary, while gantenerumab stands as a beacon of hope against Alzheimer’s, robust, long-term trials will be essential in determining its viability and safety for broader audiences.

“We may be delaying the onset of Alzheimer’s disease for millions” – Randall J. Bateman

For those interested in the latest developments on Alzheimer’s treatment, stay tuned as more groundbreaking studies emerge.

More on this topic can be explored in detail at Alzheimer’s / Dementia section on Medical News Today.